Pomegra
UK medical imaging platform Scan.com closed $220M in combined equity and debt to build what it says will be the largest diagnostic imaging network in the United States.
- $90M equity round led by Noteus Partners; $130M non-dilutive debt facility from VerisFi Capital and Atempo Growth
- Revenue doubled year-over-year to a $165M annualized run rate, with over 900,000 patients served
- Pre-IPO talks with London Stock Exchange officials are underway, though no venue or timeline has been confirmed
Lead
Scan.com, the London-based diagnostic imaging platform, closed $220 million in combined Series C financing on August 31, 2026, making it one of the larger healthtech raises out of the UK this year. The round splits into $90 million in equity led by Noteus Partners and a $130 million non-dilutive debt facility structured to fund acquisitions. Total funding now stands at roughly $277 million.
What Does Scan.com Actually Do?
Scan.com operates an API-first infrastructure layer connecting patients to diagnostic imaging providers by routing bookings, managing scheduling, and returning results. It sits between the referring clinician and the imaging center, removing the friction that in the United States often means weeks-long waits and opaque pricing. The company serves more than 900,000 patients across the UK and the US and runs an agentic AI engine that handles most of the booking and results workflow without manual intervention.
Why a $130M Debt Tranche?
The financing structure reflects the company's approach in the United States: acquisition-led network building rather than organic growth. The $130 million debt package, underwritten by VerisFi Capital and Atempo Growth, is explicitly earmarked for M&A, targeting regional scheduling networks and independent imaging groups that can be absorbed into its platform. Debt financing at this stage avoids diluting equity holders ahead of a potential public offering, which management appears to be managing carefully. The equity component drew participation from Aviva Ventures, Concord Health Partners, YZR Capital, and Oxford Capital alongside Noteus Partners.
What Does This Round Imply About the Last One?
Scan.com more than doubled revenue year-over-year to reach a $165 million annualized run rate entering the raise. That trajectory typically supports a material step-up in valuation, though the company has not disclosed its current figure. The $90 million equity tranche alongside those revenue numbers suggests pricing consistent with high-growth health infrastructure businesses rather than pure software multiples, where the complexity of healthcare logistics tends to compress valuations relative to cleaner SaaS models. Total capital deployed to date sits at approximately $277 million, and whether that efficiency holds as the company moves into a costlier US acquisition strategy remains the central execution question.
The US Bet
The US diagnostic imaging market is fragmented, slow, and expensive to navigate. Patients routinely wait weeks for non-urgent scans across many markets, and provider systems have minimal interoperability. Scan.com's model - a scheduling and routing layer sitting above existing imaging centers rather than competing with them - avoids the capital intensity of building physical infrastructure while still taking a position in every transaction it routes.
The risk is integration, not capital. Acquiring and stitching together regional scheduling platforms involves data migration, contract renegotiation, and workflow reconciliation at scale. The company's claim to build the country's largest imaging network through M&A is ambitious on a timeline; it is entirely plausible as a ten-year project and considerably harder in two.
Outlook
Scan.com is moving toward a public listing, with company representatives beginning conversations with officials at the London Stock Exchange. No venue has been confirmed and no timetable has been disclosed. At $165 million in annualized revenue and accelerating, the company has crossed into territory where an IPO is financially plausible rather than aspirational. The $220 million raise extends runway for the US acquisition push and strengthens the narrative heading into any public markets process. Whether the largest medical imaging network in the United States also proves to be the most defensible is a question that will eventually be priced.
